U.S. District Judge Matthew Kacsmaryk’s decision to put the Food and Drug Administration’s approval of the abortion drug mifepristone on hold has thrown future access to medication abortion into question nationwide and laid the foundation for a high-stakes Supreme Court battle.
The ruling, issued Friday, is set to go into effect at the end of this week unless a higher court intervenes. The Justice Department asked an appeals court to block it Monday.
In interviews, several legal and medical experts said Kacsmaryk’s decision was unprecedented and clearly ideological. His language and reasoning, they said, closely mirrored arguments and concepts put forward by the anti-abortion movement — at the expense of scientific consensus in some instances.